BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 25471691)

  • 1. Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides.
    Madura F; Rizkallah PJ; Holland CJ; Fuller A; Bulek A; Godkin AJ; Schauenburg AJ; Cole DK; Sewell AK
    Eur J Immunol; 2015 Feb; 45(2):584-91. PubMed ID: 25471691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell receptors: tugging on the anchor for a tighter hold on the tumor-associated peptide.
    Dyson J
    Eur J Immunol; 2015 Feb; 45(2):380-2. PubMed ID: 25581444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structurally silent peptide anchor modifications allosterically modulate T cell recognition in a receptor-dependent manner.
    Smith AR; Alonso JA; Ayres CM; Singh NK; Hellman LM; Baker BM
    Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
    Denkberg G; Klechevsky E; Reiter Y
    J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for clonal diversity of the human T-cell response to a dominant influenza virus epitope.
    Yang X; Chen G; Weng NP; Mariuzza RA
    J Biol Chem; 2017 Nov; 292(45):18618-18627. PubMed ID: 28931605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
    Colombetti S; Fagerberg T; Baumgärtner P; Chapatte L; Speiser DE; Rufer N; Michielin O; Lévy F
    J Immunol; 2006 Jun; 176(11):6560-7. PubMed ID: 16709813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.
    Smith SN; Sommermeyer D; Piepenbrink KH; Blevins SJ; Bernhard H; Uckert W; Baker BM; Kranz DM
    J Mol Biol; 2013 Nov; 425(22):4496-507. PubMed ID: 23954306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.
    Hoppes R; Oostvogels R; Luimstra JJ; Wals K; Toebes M; Bies L; Ekkebus R; Rijal P; Celie PH; Huang JH; Emmelot ME; Spaapen RM; Lokhorst H; Schumacher TN; Mutis T; Rodenko B; Ovaa H
    J Immunol; 2014 Nov; 193(10):4803-13. PubMed ID: 25311806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCR-induced alteration of primary MHC peptide anchor residue.
    Madura F; Rizkallah PJ; Legut M; Holland CJ; Fuller A; Bulek A; Schauenburg AJ; Trimby A; Hopkins JR; Wells SA; Godkin A; Miles JJ; Sami M; Li Y; Liddy N; Jakobsen BK; Loveridge EJ; Cole DK; Sewell AK
    Eur J Immunol; 2019 Jul; 49(7):1052-1066. PubMed ID: 31091334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
    Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
    J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
    Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
    J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
    Chen JL; Stewart-Jones G; Bossi G; Lissin NM; Wooldridge L; Choi EM; Held G; Dunbar PR; Esnouf RM; Sami M; Boulter JM; Rizkallah P; Renner C; Sewell A; van der Merwe PA; Jakobsen BK; Griffiths G; Jones EY; Cerundolo V
    J Exp Med; 2005 Apr; 201(8):1243-55. PubMed ID: 15837811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition.
    Cole DK; Edwards ES; Wynn KK; Clement M; Miles JJ; Ladell K; Ekeruche J; Gostick E; Adams KJ; Skowera A; Peakman M; Wooldridge L; Price DA; Sewell AK
    J Immunol; 2010 Aug; 185(4):2600-10. PubMed ID: 20639478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide.
    Tynan FE; Burrows SR; Buckle AM; Clements CS; Borg NA; Miles JJ; Beddoe T; Whisstock JC; Wilce MC; Silins SL; Burrows JM; Kjer-Nielsen L; Kostenko L; Purcell AW; McCluskey J; Rossjohn J
    Nat Immunol; 2005 Nov; 6(11):1114-22. PubMed ID: 16186824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
    Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
    J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive T cell receptor cross-reactivity on structurally diverse haptenated peptides presented by HLA-A2.
    Gagnon SJ; Turner RV; Shiue MG; Damirjian M; Biddison WE
    Mol Immunol; 2006 Feb; 43(4):346-56. PubMed ID: 16310048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific roles of each TCR hemichain in generating functional chain-centric TCR.
    Nakatsugawa M; Yamashita Y; Ochi T; Tanaka S; Chamoto K; Guo T; Butler MO; Hirano N
    J Immunol; 2015 Apr; 194(7):3487-500. PubMed ID: 25710913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures.
    Hausmann S; Biddison WE; Smith KJ; Ding YH; Garboczi DN; Utz U; Wiley DC; Wucherpfennig KW
    J Immunol; 1999 May; 162(9):5389-97. PubMed ID: 10228016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction.
    Khanna R; Silins SL; Weng Z; Gatchell D; Burrows SR; Cooper L
    Eur J Immunol; 1999 May; 29(5):1587-97. PubMed ID: 10359113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.